Estimate Your Risk
- Estimate Your Risk
- Low Risk
- Intermediate Risk
- High Risk
- Metastatic
Calculate
Calculate
Abnormal 1: Does not extend beyond prostate
Abnormal 2: With
extension beyond the prostate
This tool has not been reviewed or approved by any regulatory agency and is not to be used as a substitute for medical advice, diagnosis, or treatment. Hopkins makes no warranties, guarantees, or representations whatsoever regarding the accuracy, applicability, or usefulness of any information contained or referenced in this tool. Use of this tool does not establish a provider-patient relationship with Hopkins or any of its providers or affiliates. Users are advised to consult with their treating healthcare professional(s) prior to making any healthcare decisions. In using this tool, users agree that neither Hopkins nor any other party is liable for any decisions, actions, or omissions made based upon or related in any way whatsoever to the information resulting from this prediction tool. Click here to review the full Terms & Conditions.
Low-Risk Prostate Cancer
The following are typical of the population of individuals who are at low risk for prostate cancer:
- PSA 0-10 AND
- Grade Group 1 (Gleason 3+3) AND
- Clinical exam: Normal (T1c) or abnormality in one side only (cT2a)
Management Options
These men have a very low risk of dying from prostate cancer.
- Active surveillance is preferred
- Radical prostatectomy
- Radiation therapy
Clinical Trials
If you'd like to participate in a clinical trial at Johns Hopkins, visit the Institute for Clinical and Translational Research .
Intermediate-Risk Prostate Cancer
The following are typical of the population of individuals who are at intermediate risk for prostate cancer:
- PSA 10-20
- Grade Group 2 (Gleason 3+4) or Grade Group 3 (Gleason score 4+3)
- Clinical exam: Abnormality that does not extend beyond the boundary of the prostate
Management Options
- Active surveillance can be considered in select cases
- Radical prostatectomy
- Radiation therapy (sometimes with several months of hormonal suppression)
Clinical Trials
If you'd like to participate in a clinical trial at Johns Hopkins, visit the Institute for Clinical and Translational Research .
High-Risk Prostate Cancer
The following are typical of the population of individuals who are at high risk for prostate cancer:
- PSA >20 OR
- Grade Group 4 (Gleason Score 4+4)/Grade Group 5 (Gleason Score 4+5/5+4/5+5) OR
- Clinical exam: Abnormality that extends beyond the prostate with no fixation
Management Options
These men have a much higher risk of recurrence and often benefit from more aggressive combination approaches.
- Radical prostatectomy
- Radiation therapy with two to three years of hormonal suppression
Clinical Trials
If you'd like to participate in a clinical trial at Johns Hopkins, visit the Institute for Clinical and Translational Research .
Metastatic
The following are typical of the population of individuals who have metastatic prostate cancer:
- PSA
- Gleason
- Clinical exam
Management Options
- Hormone therapy
- Chemotherapy
- Radium 223
- Immunotherapy
Clinical Trials
If you'd like to participate in a clinical trial at Johns Hopkins, visit the Institute for Clinical and Translational Research .